Ista Pharmaceuticals, Inc. (ISTA) Misses Q3 EPS by 2c; Guides FY11
Tweet
Share
E-mailGet Alerts ISTA Hot Sheet
Join SI Premium – FREE
Ista Pharmaceuticals, Inc. (NASDAQ: ISTA) reported Q3 EPS of $0.09, $0.02 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $41.4 million versus the consensus estimate of $43.34 million.
Ista Pharmaceuticals, Inc. sees FY2011 EPS of at least $0.10, versus the consensus of $0.18. Ista Pharmaceuticals, Inc. sees FY2011 revenue of $160-$175 million, versus the consensus of $168.5 million.
Ista Pharmaceuticals, Inc. sees FY2011 EPS of at least $0.10, versus the consensus of $0.18. Ista Pharmaceuticals, Inc. sees FY2011 revenue of $160-$175 million, versus the consensus of $168.5 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
